Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial.
暂无分享,去创建一个
K. Dooley | E. Ticona | O. Sued | M. Lacerda | M. Aboud | B. Grinsztejn | R. Kaplan | A. Tenorio | C. Talarico | K. Angelis | N. Mwelase | Rajendra Singh | Dannae Brown | E. Belonosova | M. Ait‐Khaled | Michael R. Keegan
[1] G. Maartens,et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. , 2019, International journal of antimicrobial agents.
[2] A. Taburet,et al. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review , 2018, British journal of clinical pharmacology.
[3] Jingtao Gao,et al. Guidelines for treatment of drug-susceptible tuberculosis and patient care-2017 update , 2018 .
[4] A. Hill,et al. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials , 2017, Current opinion in HIV and AIDS.
[5] R. Pandey,et al. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study , 2017, BMC Infectious Diseases.
[6] S. Hader,et al. Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance. , 2017, The Journal of infectious diseases.
[7] M. Cotton,et al. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis , 2017, Expert opinion on pharmacotherapy.
[8] C. Kapelios,et al. Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS). , 2017, Current HIV research.
[9] S. Hader,et al. Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance. , 2017, The Journal of infectious diseases.
[10] W. Manosuthi,et al. Integrated therapy for HIV and tuberculosis , 2016, AIDS research and therapy.
[11] I. Mcnicholl,et al. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir. , 2016, AIDS reviews.
[12] C. Rouzioux,et al. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship , 2014, The Journal of antimicrobial chemotherapy.
[13] C. Delaugerre,et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. , 2014, The Lancet. Infectious diseases.
[14] R. Pandey,et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study , 2013, BMC Infectious Diseases.
[15] A. Kashuba,et al. Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir , 2013, Clinical Pharmacokinetics.
[16] Ilesh Jani,et al. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. , 2013, The Lancet. Infectious diseases.
[17] K. Dooley,et al. Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects , 2013, Journal of acquired immune deficiency syndromes.
[18] Timothy H. Self,et al. Update on rifampin, rifabutin, and rifapentine drug interactions , 2013, Current medical research and opinion.
[19] G. Maartens,et al. The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy , 2012, PloS one.
[20] Benjamin Young,et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. , 2012, The Lancet. Infectious diseases.
[21] Lerato Mohapi,et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.
[22] Anneke Grobler,et al. Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.
[23] S. Vong,et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.
[24] W. El-Sadr,et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. , 2010, The New England journal of medicine.
[25] K. Ruxrungtham,et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] K. Dooley,et al. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. , 2008, The Journal of infectious diseases.
[27] R. Jk,et al. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. , 2007 .
[28] G. Maartens,et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.
[29] J. Rockstroh,et al. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. , 2007, European journal of medical research.
[30] W. Wehrli,et al. Rifampin: mechanisms of action and resistance. , 1983, Reviews of infectious diseases.
[31] D. Mitchison,et al. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. , 1981, The American review of respiratory disease.
[32] C. Dolea,et al. World Health Organization , 1949, International Organization.